Saxagliptin added to a thiazolidinedione improves glycaemic control in patients with inadequately controlled type 2 diabetes

被引：0
|
作者：
Allen, E. [1 ]
Hollander, P. [2 ]
Li, J. [1 ]
Chen, R. [1 ]
机构：
[1] Bristol Myers Squibb Co, Princeton, NJ USA
[2] Baylor Univ, Med Ctr, Dept Endocrinol, Dallas, TX USA
来源：
DIABETOLOGIA | 2008年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
859
引用
收藏
页码：S342 / S343
页数：2
相关论文
共 50 条
  • [1] Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone
    Hollander, Priscilla
    Li, Jia
    Allen, Elsie
    Chen, Roland
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (12): : 4810 - 4819
  • [2] Saxagliptin improves glycaemic control as monotherapy in type 2 diabetes
    List, J.
    Rosenstock, J.
    Sankoh, S.
    Chen, R.
    [J]. DIABETOLOGIA, 2007, 50 : S367 - S367
  • [3] Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
    Chacra, A. R.
    Tan, G. H.
    Apanovitch, A.
    Ravichandran, S.
    List, J.
    Chen, R.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (09) : 1395 - 1406
  • [4] Saxagliptin added to metformin improves glycemic control in patients with type 2 diabetes
    Defronzo, Ralph A.
    Hissa, Miguel
    Blauwet, Mary Beth
    Chen, Roland S.
    [J]. DIABETES, 2007, 56 : A74 - A74
  • [5] The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
    DeFronzo, Ralph A.
    Hissa, Miguel N.
    Garber, Alan J.
    Gross, Jorge Luiz
    Duan, Raina Yuyan
    Ravichandran, Shoba
    Chen, Roland S.
    [J]. DIABETES CARE, 2009, 32 (09) : 1649 - 1655
  • [6] Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment
    Nowicki, M.
    Rychlik, I.
    Haller, H.
    Warren, M. L.
    Suchower, L.
    Gause-Nilsson, I.
    [J]. DIABETES OBESITY & METABOLISM, 2011, 13 (06): : 523 - 532
  • [7] Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes
    Bailey, Clifford J.
    Del Prato, Stefano
    Wei, Cheryl
    Reyner, Daniel
    Saraiva, Gabriela
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (11): : 2564 - 2569
  • [8] Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin
    Wang, Man-man
    Lin, Shuo
    Chen, Yan-ming
    Shu, Jiong
    Lu, Hong-yun
    Zhang, Yong-jun
    Xie, Ru-ying
    Zeng, Long-yi
    Mu, Pan-wei
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 108 (03) : E67 - E70
  • [9] Saxagliptin Is More Effective in β-Cell Function and Glycaemic Control than Acarbose in Aged Type 2 Diabetes Controlled Inadequately with Metformin Alone
    Wang, Man-Man
    Mu, Pan-Wei
    Zhang, Yong-Jun
    Lin, Shuo
    Chen, Yan-Ming
    Shu, Jiong
    Zeng, Long-Yi
    [J]. DIABETES, 2014, 63 : A613 - A613
  • [10] Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus
    Hollander, Priscilla L.
    Li, Jia
    Frederich, Robert
    Allen, Elsie
    Chen, Roland
    [J]. DIABETES & VASCULAR DISEASE RESEARCH, 2011, 8 (02): : 125 - 135
12345